ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma

Fuminori Teraishi, Shunsuke Kagawa, Takanori Watanabe, Yasuhisa Tango, Takeshi Kawashima, Tatsuo Umeoka, Masahiko Nisizaki, Noriaki Tanaka, Toshiyoshi Fujiwara

Research output: Contribution to journal › Article › peer-review

55 Citations (Scopus)

Fingerprint

Dive into the research topics of 'ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds